ASH17: argenx shares pop on autoimmune data

In a busy day, argenx reported positive topline results at ASH and announced a proposed U.S. public offering, shooting its stock up by over 80%.

By Suzanne Elvidge • Dec. 12, 2017

ASH17: J&J's Darzalex delivers combo win

Inserting the antibody into standard combo regimens is a key part of J&J's plan for expanding use of the drug into the frontline setting. 

By Ned Pagliarulo • Dec. 12, 2017

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

Mixed data from the biotech's hemophilia A candidate disappointed investors primed by BioMarin's compelling results.  

By Ned Pagliarulo • Dec. 11, 2017

OS miss prompts Lilly to drop Cyramza expansion

While the cancer drug improved PFS in a gastric cancer study, it didn't significantly improve overall survival — limiting its competitiveness.

By Suzanne Elvidge • Dec. 11, 2017

ASH17: Benefit of Gilead's CAR-T remains durable over longer term

More than a year after infusion, four in ten patients treated with Yescarta showed no signs of lymphoma. 

By Ned Pagliarulo • Dec. 10, 2017

ASH17: Seattle Genetics sees market opportunity in cancer combo success

Replacing a toxic chemo agent could make Adcetris a new standard therapy to treat frontline Hodgkin lymphoma.

By Ned Pagliarulo • Dec. 10, 2017

ASH17: bluebird bio makes strides in CAR-T, gene therapy

New data on the biotech's multiple myeloma CAR-T therapy were particularly impressive, boosting investor confidence. 

By Ned Pagliarulo • Dec. 9, 2017

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

Updated results from an early trial suggest an effective gene therapy for hemophilia A could be within reach.

By Ned Pagliarulo • Dec. 9, 2017

Pfizer's PARP inhibitor showcases efficacy in late-stage trial

For breast cancer patients with specific mutations, treatment with talazoparib resulted in three additional months of progression-free survival versus chemo. 

By Jacob Bell • Dec. 8, 2017

Prescribed Reading: Dealmaking begins to pick up as 2018 approaches

It's been a slow year for deals, but it looks like Gilead's buy of Kite could be a catalyst for more M&A. 

By Lisa LaMotta • Dec. 8, 2017

Arrowhead data hits the target in chronic hep B

New data from the Arrowhead ARC-520 Phase 2 trial in chronic hepatitis B points to a sustained host response.

By Suzanne Elvidge • Dec. 8, 2017

Sage stock soars with positive Phase 2 in major depression

Hope increases for patients with major depressive disorder as Sage Therapeutics' SAGE-217 meets its primary endpoint, with rapid and durable effects over six weeks of treatment.

By Suzanne Elvidge • Dec. 8, 2017

Chasing leaders, Juno rides CAR-T momentum into ASH

This year's ASH conference will be an important milestone in Juno's comeback bid, showcasing early progress of its lead CAR-T therapy in lymphoma. 

By Ned Pagliarulo • Dec. 7, 2017

Roche's Tecentriq combo cuts risk of lung cancer progression

Detailed results from the Swiss pharma's IMpower150 study boost Tecentriq's profile in the frontline lung cancer setting.

By Ned Pagliarulo • Dec. 7, 2017

Madrigal NASH data sounds a sweet note, stock soars

The market is playing the biotech's tune, as positive NASH data pleases shareholders.

By Suzanne Elvidge • Dec. 7, 2017

FDA cautiously lifts holds on combo studies of checkpoint inhibitors

Concerns of a potential class-wide safety risk had prompted the agency to shut down several studies pairing PD-1/L1 blockers with immunomodulatory drugs in multiple myeloma.

By Ned Pagliarulo • Dec. 6, 2017

Galectin drops 40% on negative NASH result

The biotech's stock took a major hit when its NASH drug didn't work in the overall study population.

By Lisa LaMotta • Dec. 5, 2017

J&J, Sanofi ranked best for clinical trial transparency

Both companies had 100% transparency rates related to new drugs they received approval for in 2014, according to a new study from Bioethics International.

By Jacob Bell • Dec. 5, 2017

Ra shares tank on Soliris comparison

Despite positive data for RA101495, the markets haven't seemed impressed, and stock value has dropped by over 37% at close.

By Suzanne Elvidge • Dec. 5, 2017

Ironwood pushing through mid-stage trials with nephropathy drug

Safety and PK studies showed early signs of benefits for Ironwood's lead pipeline candidate.

By Suzanne Elvidge • Dec. 5, 2017

Updated: Sanofi discontinues C. diff candidate in blow to vaccine unit

Disclosure of the setback came on the heels of a damaging admission by Sanofi that its dengue vaccine could intensify subsequent infections in certain patients. 

By Ned Pagliarulo • Dec. 4, 2017

7 Biopharmas to watch at ASH 2017

This year's ASH meeting looks to be a key milestone for several closely watched cell and gene therapy companies. 

By Ned Pagliarulo • Dec. 4, 2017

Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC

Imfinzi's miss in non-small cell lung cancer was a huge setback for the British pharma and could relegate the drug as a never-was in the checkpoint inhibitor race.

By Lisa LaMotta • Dec. 4, 2017

Biotech of the Year: Vertex Pharmaceuticals

Vertex watched its stock more than double in 2017 as the company cornered the multi-billion-dollar cystic fibrosis market with strong products and a promising pipeline.

By Jacob Bell • Dec. 4, 2017

Disruption of the Year: Long-Acting Hemophilia Drugs

Longer-acting treatments and gene therapies are likely to steal away hundreds of millions of dollars worth of revenue from established products in the coming years.

By Jacob Bell • Dec. 4, 2017